Company Profile
Harrow, Inc. Stock Price, News & Analysis
- Ticker:
- HROW
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
39.92 USD (+1.29%)
Close
Last updated: August 6, 2026
1.22B USD
Market cap
Why the stock is moving
The latest company update was “Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease”. HROW changed 1.29% and closed at $39.92 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this fda / regulatory update.
Company overview
Ophthalmic Pharmaceutical Portfolio
Harrow is a U.S. ophthalmic pharmaceutical company commercializing branded and compounded medicines for eye-care professionals. Its portfolio addresses conditions managed in optometry, ophthalmology and surgical settings.
Dry-Eye Franchise
VEVYE is a cyclosporine ophthalmic solution for the signs and symptoms of dry-eye disease. It is positioned as a differentiated prescription option within a large chronic-treatment market.
Surgical and Retina Products
IHEEZO is a single-use ocular anesthetic gel used for ophthalmic procedures. Harrow also markets additional products serving retina practices and other segments of eye care through a specialized commercial organization.
Future catalysts
Harrow's catalysts are VEVYE and IHEEZO commercialization, plus continued ophthalmology portfolio expansion. The company is still building out a broader eye-care base that can support more durable growth.
Recent news
- 01
- 02
- 03
- 04
- 05
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Source: Harrow, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Harrow, Inc. (HROW)?
Harrow, Inc. (HROW) most recently closed at 39.92 USD, a +1.29% move versus the previous session.
What is the market cap of Harrow, Inc. (HROW)?
Harrow, Inc. currently has a market capitalization of 1.22B USD on BioPharmSignal.
What does Harrow, Inc. do?
Ophthalmic Pharmaceutical Portfolio Harrow is a U.S. ophthalmic pharmaceutical company commercializing branded and compounded medicines for eye-care professionals. Its portfolio addresses conditions managed in optometry, ophthalmology and surgical settings. Dry-Eye Franchise VEVYE is a cyclosporine ophthalmic solution for the signs and symptoms of dry-eye...
On which exchange is HROW stock listed?
Harrow, Inc. (HROW) is associated with NASDAQ, United States, Biopharma.
What is Ophthalmic?
Ophthalmic Pharmaceutical Portfolio Harrow is a U.S.
Which conditions is Harrow, Inc. targeting with Ophthalmic?
Harrow, Inc. is associated with ophthalmology based on its company overview and current catalyst commentary.
How does Harrow, Inc. describe recent progress with Ophthalmic?
Harrow's catalysts are VEVYE and IHEEZO commercialization, plus continued ophthalmology portfolio expansion. The company is still building out a broader eye-care base that can support more durable growth.
What is Pharmaceutical?
Ophthalmic Pharmaceutical Portfolio Harrow is a U.S.